header logo image

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

May 24th, 2024 2:52 am

Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)

Read the rest here:
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

Related Post

Tags:

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick